Axitinib-d3

Axitinib-d3 (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively[1].

Product Specifications

CAS Number

[1126623-89-9]

Product Name Alternative

AG-013736-d3

UNSPSC

12352005

Target

VEGFR

Type

Isotope-Labeled Compounds

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

98.07

Solubility

DMSO : 5.56mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC([2H])([2H])[2H])C1=CC=CC=C1SC2=CC3=C(C=C2)C(/C=C/C4=NC=CC=C4)=NN3

Molecular Formula

C22H15D3N4OS

Molecular Weight

389.49

References & Citations

[1]Fenton BM, et al. The addition of AG-013736 to rractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res. 2007 Oct 15;67 (20) :9921-8|[2]Hu-Lowe DD, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008 Nov 15;14 (22) :7272-83|[3]Allen E, et al. Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell Rep. 2016 May 10;15 (6) :1144-60.